Condition
Avatrombopag
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Avatrombopag
Research Leaders
8 sponsors active, led by Tianjin Medical University Second Hospital
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 2 (2)
Trial Status
Unknown2
Clinical Trials (2)
Research Network
Common Treatments
- Avatrombopag2
Active Sponsors
- Tianjin Medical University Second Hospital1
- Tianjin People's Hospital1
- Henan Cancer Hospital1
- Peking Union Medical College Hospital1
- Tianjin Medical University Cancer Institute and Hospital1
Top Investigators
Peking Union Medical College Hospital (PUMCH)
Chinese Academy of Medical Science and Blood Disease Hospital
Related Conditions
- Chemotherapyinduced Thrombocytopenia1
- Thrombocytopenia1